Hot Features
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, non... Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0566 | -16.8152109329 | 0.3366 | 0.36 | 0.2705 | 114790 | 0.33050431 | CS |
| 4 | -0.0525 | -15.7894736842 | 0.3325 | 0.3999 | 0.2705 | 80193 | 0.3281585 | CS |
| 12 | -0.2325 | -45.3658536585 | 0.5125 | 0.55 | 0.2705 | 105500 | 0.39762358 | CS |
| 26 | -0.12 | -30 | 0.4 | 0.6666 | 0.262 | 2210198 | 0.43495971 | CS |
| 52 | -4.73 | -94.4111776447 | 5.01 | 9.1796 | 0.262 | 1968578 | 1.12289129 | CS |
| 156 | -4.73 | -94.4111776447 | 5.01 | 9.1796 | 0.262 | 1968578 | 1.12289129 | CS |
| 260 | -4.73 | -94.4111776447 | 5.01 | 9.1796 | 0.262 | 1968578 | 1.12289129 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.